IP Library Granted Patent US 8,394,411
Granted Patent B2
US 8,394,411 · App. 12/598,684 · Granted Mar 12, 2013

Papillomavirus pseudoviruses for detection and therapy of tumors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,394,411
App. No.
12/598,684
Granted
Mar 12, 2013
Kind
B2
Abstract

Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP).

Claims (21)

1. A method of inhibiting the proliferation of cancer cells and/or killing cancer cells comprising

administering to a subject having cancer a composition that comprises a therapeutic agent formulated with a papilloma pseudovirus or a papilloma VLP, wherein the therapeutic agent is selected from the group consisting of:

a) a gene selected from the group consisting of:

i) a tumor suppressor gene;

ii) a pro-apototic gene;

iii) a gene encoding a cytokine, a lymphokine, a monokine, a growth factor, an enzyme or a hormone;

iv) an immunomodulatory gene;

v) a gene encoding a cytotoxic polypeptide; and,

vi) a suicide gene;

b) a cytotoxin;

c) a radionuclide;

d) a pro-drug; and

e) a therapeutic nucleic acid.

2. The method of claim 1 , wherein said therapeutic agent is chemically coupled to said pseudovirus or said VLP.

3. The method of claim 1 , wherein said therapeutic agent is incorporated within said pseudovirus or said VLP.

4. The method of claim 1 , wherein said therapeutic agent is a toxin.

5. The method of claim 1 , wherein said therapeutic agent is ganciclovir or acyclovir.

6. The method of claim 1 , wherein said therapeutic agent is oligo T or a nucleic acid expressing oligo T.

7. The method of claim 6 , wherein said oligo T is less than or equal to 200, 175, 150, 125, 100, 95, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, or 10 nucleotides.

8. The method of claim 1 , wherein said therapeutic agent is a nucleic acid expressing oligo T and said nucleic acid is operably joined to a Pol III promoter.

9. The method of claim 1 , wherein said therapeutic agent is a radionuclide.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 11, 2018
From: ADVENT LIFE SCIENCES FUND I, L.P.
To: AURA BIOSCIENCES, INC.
Reel/Frame 044593/0304 →
SECURITY INTEREST Recorded Sep 26, 2016
From: AURA BIOSCIENCES, INC.
To: ADVENT LIFE SCIENCES FUND I, L.P.
Reel/Frame 039851/0860 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2010
From: ROBERTS, JEFF; LOWY, DOUGLAS R.; SCHILLER, JOHN T.
To: THE USA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
Reel/Frame 023909/0612 →